This case report highlights that abciximab may not always be effective in reversing refractory no-reflow phenomenon during primary stenting for acute myocardial infarction.
Abciximab may fail in refractory no-reflow during primary stenting; this case leaves open need for alternative strategies in acute MI.
Glycoprotein IIb/IIIa antagonists have been shown to be effective in reducing thrombotic complications prior to high-risk coronary interventions. Some studies have reported improved coronary flow after abciximab in slow or no-reflow phenomenon. We report a case in which abciximab did not clear the thrombotic occlusion or restore artery flow. Further studies are needed into the refractory no-flow phenomenon.
No takes yet. Share an insight, caveat, or question.
Banai et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: